SVS-VQI 当代基准:腹主动脉瘤腔内修复术
基于 SVS-VQI 登记 2011–2024 年 90,370 例 EVAR,择期、症状性完整瘤、破裂瘤住院死亡率分别为 0.5%、2.2%、21.5%,择期死亡率随时期下降。围术期并发症下降,但指南直径阈值依从性、优化药物治疗和影像随访仍有提升空间。
要点
- 择期 EVAR 住院死亡率为 0.5%,破裂为 21.5%,可作为当代基准。
- 2014 年后经皮股动脉入路普及,2022–2024 达 89.4%。
- 择期男性直径阈值不依从率从 46% 降至 40%,女性从 23% 降至 21%。
核心结论
- EVAR 住院死亡率持续较低,围术期并发症随时间改善,但指南直径阈值依从性、优化药物治疗和影像监测仍有提升空间。
- 该研究建立了当代美国 EVAR 全国基准,供中心间比较和质量改进参考。
研究设计与样本
- 基于 SVS-VQI EVAR 登记的前瞻性非索赔数据,纳入 2011–2024 年 >400 中心共 90,370 例 EVAR。
- 按指征分为择期 76,350 例(85%)、症状性完整瘤 8,349 例(9%)、破裂 5,671 例(6%)。
- 主要终点为住院死亡率,次要终点包括住院并发症、指南直径阈值依从性、出院指南导向药物治疗和 1 年随访依从性。
主要发现
- 择期 EVAR 住院死亡率为 0.5%(95%CI 0.42–0.52),症状性完整瘤为 2.2%(95%CI 1.91–2.56),破裂为 21.5%(95%CI 20.4–22.6)。
- 择期死亡率从 2011–2013 的 0.6% 降至 2022–2024 的 0.4%(P=.02),症状性完整瘤从 2.3% 降至 1.8%(P=.14),破裂从 24.0% 降至 20.6%(P=.09)。
- 所有指征的住院复合并发症率显著下降(P<.001)。
- 经皮股动脉入路总体率为 81.1%(95%CI 80.8–81.4),2022–2024 当代基准为 89.4%(95%CI 89.1–89.8)。
- 2024 年出院时 87% 使用抗血小板药、83% 使用他汀、74% 两者联用;2022 年 1 年临床随访 79%,影像监测 51%。
关键数值与推荐
- SVS 指南认可的择期直径治疗阈值:男性 ≥5.5 cm,女性 ≥5.0 cm。
- 择期男性直径阈值不依从率从 46% 降至 40%,女性从 23% 降至 21%。
- 择期 EVAR 住院死亡率当代基准为 0.5%(95%CI 0.42–0.52)。
临床怎么用
- 可将本院 EVAR 住院死亡率、经皮入路比例和出院药物治疗率与上述全国基准对比。
- 应关注择期 EVAR 直径阈值依从性,减少不符合指南的过大或过小瘤体干预。
- 需加强出院他汀和抗血小板治疗及术后影像监测的落实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Society for Vascular Surgery Vascular Quality Initiative (SVS-VQI) Endovascular Abdominal Aortic Aneurysm Repair (EVAR) registry represents the largest and most comprehensive prospectively maintained nonclaim-based dataset of endoluminal repairs in the North America. As part of the SVS-VQI benchmarking initiative, we sought to define national reference standards for patient selection, perioperative outcomes, and process-of-care metrics. METHODS: All EVAR procedures from 2011 to 2024 were included and stratified by indication as elective, symptomatic (intact and nonruptured), or ruptured. The primary end point was in-hospital mortality; secondary end points included in-hospital complications, adherence to SVS guideline-endorsed elective diameter treatment thresholds (men ≥ 5.5 cm; women ≥ 5.0 cm), discharge prescription of guideline-directed medical therapy, and 1-year follow-up compliance. Risk-adjusted observed-to-expected mortality ratios were derived from mixed-effects logistic regression models incorporating patient- and procedure-level covariates. Temporal trends were analyzed using linear and logistic regression across four periods: 2011 to 2013, 2014 to 2017, 2018 to 2021, and 2022 to 2024. RESULTS: Among 90,370 EVARs performed across >400 centers, 76,350 (85%) were elective, 8349 (9%) symptomatic-intact, and 5671 (6%) ruptured. Mean patient age was 73.5 ± 8.8 years, and 17,531 (19%) were women. Adoption of percutaneous femoral access increased markedly after 2014, exceeding 80% of all cases across the study period [overall rate, 81.1%; 95% confidence interval (CI), 80.8-81.4] and reaching a contemporary benchmark of 89.4% (95% CI, 89.1-89.8) in 2022 to 2024. In-hospital mortality was 0.5% (95% CI, 0.42-0.52) for elective, 2.2% (95% CI, 1.91-2.56) for symptomatic-intact, and 21.5% (95% CI, 20.4-22.6) for ruptured repairs. Over time, mortality declined from 0.6% in 2011 to 2013 to 0.4% in 2022 to 2024 (P = .02) for elective cases, from 2.3% to 1.8% (P = .14) for symptomatic-intact, and from 24.0% to 20.6% (P = .09) for ruptures. Composite in-hospital complication rates decreased significantly across all indications (P < .001). Among elective repairs, adherence to diameter-based guidelines improved modestly, with male noncompliance decreasing from 46% to 40% and female noncompliance declining from 23% to 21%. In 2024, 87% of patients were discharged on an antiplatelet agent, 83% on a statin, and 74% on both. By 2022, one-year clinical follow-up reached 79%, whereas imaging surveillance was reported in 51%. CONCLUSIONS: EVAR outcomes within the SVS-VQI demonstrate persistently low in-hospital mortality and improving perioperative morbidity over time. Despite these gains, opportunities remain to improve adherence to societally endorsed diameter treatment thresholds, optimal medical therapy, and post-EVAR imaging surveillance. These findings establish contemporary national benchmarks for EVAR performance and provide reference standards for center-level comparison and quality improvement within the SVS-VQI.
引用
- Scali ST, Stone DH, Neal D, et al. Society for Vascular Surgery Vascular Quality Initiative Contemporary Benchmarks: Endovascular Abdominal Aortic Aneurysms. J Vasc Surg. 2026. PMID: 42498186. doi:10.1016/j.jvs.2026.07.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。